GO28397(vemurafenib + acenocoumarol)


Protocolnummer:
Gesloten

Ziekenhuizen:
GO28397(vemurafenib + acenocoumarol)

Titel:
> A phase 1, open-label, multicenter, 3-period, fixed-sequence study to investigate the effect of vemurafenib on the pharmacokinetics of a single oral dose of acenocoumarol in patients with BRAF V600-mutation-positive metastatic malignancy.

Behandeling:
Acenocoumarol 4mg on day 1 and day 23, vemurafenib on days 4-23

Stadium:
Stadium irresectable IIIc/IV

Belangrijkste in/exclusiecriteria:
In: 18-70 years of age, ECOG performance status of 0-2, adequate hematologic and end organ function. Ex: Prior treatment with vemurafenib or other BRAF inhibitor within 42 days of day 1, history of myocardial infarction within 6 months, history of bleeding or coagulation disorders, significant liver disease, alcohol abuse or active hepatitis B or C infection.

Contactpersoon:

Alle trials